<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479010</url>
  </required_header>
  <id_info>
    <org_study_id>HM13729</org_study_id>
    <nct_id>NCT01479010</nct_id>
  </id_info>
  <brief_title>Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension</brief_title>
  <official_title>Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label non-randomized, pilot study to evaluate the effect of Interleukin-1
      blockade on exercise capacity in patients with pulmonary hypertension. Subjects will undergo
      cardiopulmonary exercise testing at baseline, and after 4 weeks treatment with Anakinra
      (recombinant human Interleukin-1 receptor antagonist.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment issues, critical investigators left institution
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Interval Change From Baseline in Peak VO2</measure>
    <time_frame>28 days</time_frame>
    <description>Peak VO2 will be measured during a standardized cardiopulmonary exercise test in which patients exercise on a treadmill while breathing through a mask.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Interval Change From Baseline in the Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope)</measure>
    <time_frame>28 days</time_frame>
    <description>VE/VCO2 slope will be measured during a standardized cardiopulmonary exercise test in which patients exercise on a treadmill while breathing through a mask.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interval Change From Baseline in Biomarkers (High-sensitivity C-reactive Protein, Whole Blood Assay, Brain Natriuretic Peptide)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval Change From Baseline in Heart Failure Symptoms as Measured by Duke Activity Status Index (DASI)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Interval Changes in Biomarkers, Peak VO2, and VE/VCO2</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events and Hospitalizations</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Exercise Time</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Uptake Efficiency Slope</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra 100 mg subcutaneously daily</intervention_name>
    <description>Anakinra 100 mg subcutaneously daily</description>
    <arm_group_label>Anakinra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Diagnosis of PAH (from prior right heart catheterization), with functional class III
             symptoms of right ventricle failure despite optimal PAH therapy

          -  Mean pulmonary artery pressure &gt;25 mmHg

          -  Pulmonary capillary wedge pressure &lt;15 mmHg

          -  Pulmonary vascular resistance &gt;3 wood units

        Exclusion Criteria:

          -  PAH due to connective tissue disease (including scleroderma), interstitial lung
             disease (total lung capacity &lt;65% predicted value), or cirrhosis (portopulmonary
             hypertension)

          -  Angina or electrocardiograph (ECG) changes that limit maximum exertion during
             cardiopulmonary exercise testing or baseline ECG changes that limit the ability to
             detect ischemia (i.e. left bundle-branch block).

          -  Recent (&lt;14 days) use of anti-inflammatory drugs (not including NSAIDs), chronic
             inflammatory disorder (including but not limited to rheumatoid arthritis, systemic
             lupus erythematosus), malignancy, active infection, or any comorbidity limiting
             survival or ability to complete the study

          -  Severe kidney dysfunction (eGFR &lt;30 mL/min)

          -  Thrombocytopenia (&lt;50,000/mm3), or neutropenia (absolute neutrophil count &lt;1,500/mm3)

          -  Refusal by a woman of childbearing potential (not post-menopausal or surgically
             sterile) to use a medically acceptable form of birth control (including, but not
             limited to, a diaphragm, an intrauterine device (IUD), progesterone implants or
             injections, oral contraceptives, the double-barrier method, or a condom) throughout
             the duration of the study

          -  History of hypersensitivity to anakinra or E. coli products

          -  Latex or rubber allergy

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Van Tassell, Pharm D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2011</study_first_posted>
  <results_first_submitted>May 20, 2015</results_first_submitted>
  <results_first_submitted_qc>May 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2015</results_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Interval Change From Baseline in Peak VO2</title>
        <description>Peak VO2 will be measured during a standardized cardiopulmonary exercise test in which patients exercise on a treadmill while breathing through a mask.</description>
        <time_frame>28 days</time_frame>
        <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Median Interval Change From Baseline in Peak VO2</title>
          <description>Peak VO2 will be measured during a standardized cardiopulmonary exercise test in which patients exercise on a treadmill while breathing through a mask.</description>
          <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Interval Change From Baseline in the Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope)</title>
        <description>VE/VCO2 slope will be measured during a standardized cardiopulmonary exercise test in which patients exercise on a treadmill while breathing through a mask.</description>
        <time_frame>28 days</time_frame>
        <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Median Interval Change From Baseline in the Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope)</title>
          <description>VE/VCO2 slope will be measured during a standardized cardiopulmonary exercise test in which patients exercise on a treadmill while breathing through a mask.</description>
          <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interval Change From Baseline in Biomarkers (High-sensitivity C-reactive Protein, Whole Blood Assay, Brain Natriuretic Peptide)</title>
        <time_frame>28 days</time_frame>
        <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Interval Change From Baseline in Biomarkers (High-sensitivity C-reactive Protein, Whole Blood Assay, Brain Natriuretic Peptide)</title>
          <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interval Change From Baseline in Heart Failure Symptoms as Measured by Duke Activity Status Index (DASI)</title>
        <time_frame>28 days</time_frame>
        <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Interval Change From Baseline in Heart Failure Symptoms as Measured by Duke Activity Status Index (DASI)</title>
          <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Interval Changes in Biomarkers, Peak VO2, and VE/VCO2</title>
        <time_frame>28 days</time_frame>
        <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Interval Changes in Biomarkers, Peak VO2, and VE/VCO2</title>
          <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Adverse Events and Hospitalizations</title>
        <time_frame>28 days</time_frame>
        <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Adverse Events and Hospitalizations</title>
          <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Exercise Time</title>
        <time_frame>28 days</time_frame>
        <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Exercise Time</title>
          <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Uptake Efficiency Slope</title>
        <time_frame>28 days</time_frame>
        <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Uptake Efficiency Slope</title>
          <population>Due to the small number of participants, results are not included to protect the privacy of individual participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Anakinra</title>
          <description>Anakinra 100 mg subcutaneously daily: Anakinra 100 mg subcutaneously daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin Van Tassell, PharmD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>8048284583</phone>
      <email>bvantassell@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

